Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH) in a report published on Saturday. The brokerage issued a sell rating on the stock.

Bio-Path Stock Up 6.3 %

BPTH stock opened at $4.02 on Friday. The firm has a market capitalization of $2.73 million, a PE ratio of -0.10 and a beta of 0.66. The stock’s 50 day moving average is $7.17 and its 200-day moving average is $9.01. Bio-Path has a twelve month low of $3.51 and a twelve month high of $44.80.

Bio-Path (NASDAQ:BPTH) last announced its earnings results on Friday, March 8th. The company reported ($5.40) EPS for the quarter, meeting the consensus estimate of ($5.40). During the same quarter in the previous year, the company posted ($10.60) earnings per share. On average, equities research analysts anticipate that Bio-Path will post -20.8 earnings per share for the current fiscal year.

Institutional Trading of Bio-Path

Institutional investors and hedge funds have recently modified their holdings of the business. Virtu Financial LLC bought a new stake in shares of Bio-Path during the 1st quarter worth $38,000. Citadel Advisors LLC purchased a new stake in Bio-Path during the third quarter worth about $35,000. Renaissance Technologies LLC bought a new stake in Bio-Path in the second quarter worth about $70,000. Vanguard Group Inc. boosted its stake in Bio-Path by 77.5% in the fourth quarter. Vanguard Group Inc. now owns 270,029 shares of the company’s stock valued at $125,000 after acquiring an additional 117,914 shares during the last quarter. Finally, Walleye Capital LLC bought a new position in shares of Bio-Path during the 3rd quarter valued at approximately $77,000. 5.74% of the stock is owned by hedge funds and other institutional investors.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.